Horizon Therapeutics
1 Horizon Way
Deerfield
IL
60015
United States
598 articles with Horizon Therapeutics
-
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
3/14/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD.
-
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
3/12/2023
Horizon Therapeutics plc announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease patients with DON, the majority of whom had not previously responded to other treatments.
-
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
3/1/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced fourth-quarter and record full-year 2022 financial results.
-
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
2/28/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that applications for its 2023 #RAREis Global Advocate Grant are open through March 31, 2023.
-
New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines
2/23/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two post-hoc analyses of the N-MOmentum clinical trial of UPLIZNA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) will be presented at the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, February 23-25, 2023, in San Diego.
-
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
1/30/2023
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets.
-
Sen. Elizabeth Warren (D-MA) voiced concerns to the FTC regarding the prospective acquisitions of Horizon Pharmaceuticals and Opiant Pharmaceuticals by Amgen and Indivior.
-
Horizon Therapeutics' dazodalibep met the primary endpoint in a second straight Phase II trial for Sjögren’s syndrome.
-
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population
1/18/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the primary endpoint was met for the second population in its Phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome.
-
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
1/4/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab.
-
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
12/20/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
-
Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.
-
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
12/8/2022
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457.
-
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
12/8/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first subject has been dosed in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457.
-
Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. This leaves Amgen and Sanofi at the bidding table.
-
Shares of Horizon Therapeutics are soaring in premarket trading Wednesday after the rare disease company confirmed it is being courted for a potential acquisition by three pharma giants.
-
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
11/23/2022
Xeris Biopharma Holdings, Inc. today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP).
-
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
11/16/2022
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA ® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED).
-
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
11/16/2022
Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious autoimmune and inflammatory conditions.
-
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
11/10/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November.